In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Risk Scores in Secondary Cardiovascular Prevention

Martijn Scherrenberg, Secondary Prevention and Rehabilitation Section

Coronary Artery Disease (Chronic)
Risk Factors and Prevention

The case

A 62-year-old male patient presents for follow-up six weeks after experiencing an anterior ST-elevation myocardial infarction (STEMI) treated successfully with percutaneous coronary intervention (PCI). He has a history of hyperlipidemia and hypertension. Cardiovascular disease and diabetes mellitus are common in his family, and he is concerned about his long-term prognosis. At night in bed, he experiences bouts of fast, irregular palpitations. Clinical examination is unremarkable and shows regular pulse at 64 beats per minute, and blood pressure 125/75 mmHg. His recent lab results demonstrate normal glycated haemoglobin (HbA1c), well controlled low density lipoprotein (LDL) cholesterol and elevated high sensitivity C-reactive protein (hs-CRP). 

Test your knowledge

 

Note: The views and opinions expressed on this page are those of the author and may not be accepted by others. While every attempt is made to keep the information up to date, there is always going to be a lag in updating information. The reader is encouraged to read this in conjunction with appropriate ESC Guidelines. The material on this page is for educational purposes and is not for use as a definitive management strategy in the care of patients. Quiz material on the site are only examples and do not guarantee outcomes from formal examinations.

References

Question 1: Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model, EJPC, 08 April 2024, https://doi.org/10.1093/eurjpc/zwae096

Question 2: Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions, EJPC, 16 May 2024, https://doi.org/10.1093/eurjpc/zwae174

Question 3: Development and validation of a prognostic score integrating remote heart failure symptoms and clinical variables in mortality risk prediction after myocardial infarction: the PragueMi score, EJPC, 18 March 2024, https://doi.org/10.1093/eurjpc/zwae114

Question 4: Trends in population attributable fraction of modifiable risk factors for cardiovascular diseases across three decades, EJPC, 27 June 2024, https://doi.org/10.1093/eurjpc/zwae219

Question 5: Applying the HARMS2-atrial fibrillation risk score for Japanese population: an analysis of a nationwide epidemiological dataset Get access Arrow, EJPC, 19 March 2024, https://doi.org/10.1093/eurjpc/zwae111